Shamim et al., 2020 - Google Patents
Potential strategies for combating COVID-19Shamim et al., 2020
View HTML- Document ID
- 5416066888815154447
- Author
- Shamim S
- Khan M
- Kharaba Z
- Ijaz M
- Murtaza G
- Publication year
- Publication venue
- Archives of virology
External Links
Snippet
Coronavirus disease 2019, also known as COVID-19, is caused by a novel coronavirus named severe acute respiratory syndrome coronavirus 2, or SARS-CoV-2. The infection has now catapulted into a full-blown pandemic across the world, which has affected more than 2 …
- 200000000015 coronavirus disease 2019 0 title abstract description 122
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane, progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Chakraborty et al. | COVID-19: An overview of the current pharmacological interventions, vaccines, and clinical trials | |
| Ye et al. | Clinical efficacy of lopinavir/ritonavir in the treatment of Coronavirus disease 2019. | |
| Pal et al. | Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2): an update | |
| Sheervalilou et al. | COVID‐19 under spotlight: A close look at the origin, transmission, diagnosis, and treatment of the 2019‐nCoV disease | |
| Kabir et al. | nCOVID-19 pandemic: from molecular pathogenesis to potential investigational therapeutics | |
| Shamim et al. | Potential strategies for combating COVID-19 | |
| Alvi et al. | Pharmacological and non-pharmacological efforts at prevention, mitigation, and treatment for COVID-19 | |
| Liu et al. | From SARS to COVID-19: What lessons have we learned? | |
| Barati et al. | Potential drugs and remedies for the treatment of COVID-19: a critical review | |
| Yu et al. | Recent understandings toward coronavirus disease 2019 (COVID-19): from bench to bedside | |
| Bhagat et al. | Novel corona virus (COVID-19) pandemic: current status and possible strategies for detection and treatment of the disease | |
| Borah et al. | Current scenario and future prospect in the management of COVID-19 | |
| Kaur et al. | Coronavirus disease (COVID‐19): An updated review based on current knowledge and existing literature for dermatologists | |
| Singh et al. | Recent advances in pathophysiology, drug development and future perspectives of SARS-CoV-2 | |
| Karcıoğlu et al. | COVID-19: The biggest threat of the 21st century: In respectful memory of the warriors all over the world | |
| Gharehbaghi et al. | COVID-19 in children and neonates: a comprehensive review article | |
| Karthika et al. | COVID-19, the firestone in 21st century: a review on coronavirus disease and its clinical perspectives | |
| Wu et al. | Evolution and major changes of the diagnosis and treatment protocol for COVID‐19 patients in China 2020–2023 | |
| Athari et al. | Updates on coronavirus (COVID-19) and kidney. | |
| Song et al. | Protease inhibitor use in COVID-19 | |
| Naveed et al. | Various evidence-based hypothetical and experimental treatment approaches and their effectiveness against COVID-19 worldwide: a comprehensive literature review | |
| Nomier et al. | Distinctive Therapeutic Strategies against Corona Virus19 (COVID-19): A Pharmacological Review. | |
| Siddique et al. | Evidence and speculations: vaccines and therapeutic options for COVID-19 pandemic | |
| Rasul et al. | Mycoplasma pneumoniae‐Induced‐Stevens Johnson Syndrome: Rare Occurrence in an Adult Patient | |
| Hamid et al. | Hantavirus Cardiopulmonary Syndrome and Diffuse Alveolar Hemorrhage in the Era of COVID‐19 |